
Abcam
Partners & Customers
10Service Providers
2About Abcam
Abcam (NASDAQ: ABCM) supplies products in research areas such as cancer, cardiovascular, chromatin and nuclear signaling, immunology, neuroscience, and stem cells. The company provides a range of non-primary antibody products such as secondary antibodies, kits, proteins, peptides, and lysates. It was founded in 1998 and is based in Cambridge, United Kingdom.

Want to inform investors similar to Abcam about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Abcam News
Sep 23, 2023
Washington, DC. Steven M. Rales is an American businessman and film producer, and chairman of Danaher Corporation. He is listed as the 118th richest person in America, with a value of $3.2 billion. Raised in a Jewish family, Rales is one of four sons of Norman and Ruth Rales. His father was raised in an orphanage, the Hebrew Orphan Asylum in New York City and later became a businessman who sold his bui (Photo by Mark Reinstein/Corbis via Getty Images) Corbis via Getty Images The Rales brothers, Steven M. Rales and Mitchell P. Rales, are renowned American businessmen and investors who have left an indelible mark on the corporate landscape, primarily through their association with Danaher Corporation. Their journey to prominence began in the 1980s, when they, along with a group of investors, acquired Danaher, a struggling conglomerate. Under their astute leadership, the company underwent a remarkable transformation, evolving into a highly successful, diversified industrial giant. The Rales brothers are celebrated for their disciplined and strategic approach to business. They have consistently sought out industrial and technology companies with substantial growth potential, instilling principles of lean manufacturing and continuous improvement inspired by the Japanese concept of Kaizen. Their influence led Danaher to diversify into various sectors, including healthcare, life sciences, diagnostics, and environmental solutions. In 2015, they made a significant strategic move by splitting Danaher into two separate entities: Danaher Corporation, focusing on science and technology, and Fortive Corporation, centered on industrial technology. This restructuring allowed each company to concentrate more effectively on its distinct market opportunities. Beyond their business acumen, the Rales brothers are known for their philanthropic endeavors, supporting various causes, including the arts and education. Their wealth and business achievements have consistently earned them a place on Forbes' list of the wealthiest Americans. In essence, the Rales brothers' legacy lies in their ability to steer companies towards success, their commitment to philanthropy, and their enduring impact on the corporate world. UKRAINE - 2021/05/24: In this photo illustration, Danaher Corporation logo is seen displayed on a ... [+] smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images MORE FOR YOU In the annals of business and finance, the Rales brothers emerged as figures of profound success, and yet, they were known for their propensity for discretion. Their narrative, a tale of exceptional accomplishment, was enshrouded in an aura of secrecy, a facet that perpetually piqued the curiosity of those seeking insights into their methodologies and motivations. These two brothers, renowned for orchestrating transformative changes, had undertaken the stewardship of Danaher Corporation, a struggling conglomerate, and masterminded its evolution into a global industrial juggernaut. However, amid their substantial influence and wealth, the Rales brothers remained conspicuously private individuals. Though their footprint could be discerned within the realm of commerce, details pertaining to their personal lives remained elusive. It was postulated that their unassuming demeanor mirrored their modus operandi in business: unobtrusive, methodical, and concentrated. Whereas many individuals occupying their stature often gravitated toward the limelight, the Rales brothers opted to let their actions and outcomes resound more emphatically than their verbal pronouncements. The veil of secrecy enveloping them lent an air of intrigue to their narrative. Some conjectured that their predilection for discretion was a tactical maneuver, affording them the freedom to operate behind the scenes, unburdened by the scrutiny that typically accompanies individuals of high-profile status. Others perceived it as a manifestation of their reverence for the craft of business itself, wherein outcomes trumped ostentation. Ultimately, the chronicle of the Rales brothers underscored the notion that triumph could be attained with quietude, away from the public gaze. Their proclivity for secrecy heightened the allure of their journey, leaving those who endeavored to decipher their enigma with a sense of wonderment and fascination. Thus, the enigmatic legacy of the Rales brothers persisted in its capacity to captivate the imagination of the business domain. The Kaizen Philosophy Danaher Corporation designs, manufactures, and markets medical, industrial, and commercial products and services from its headquarters in Washington, D.C. It has historically attempted to keep a minimal public profile and has grown primarily through acquisitions. Danaher was one of the first companies to implement the Kaizen philosophy. Kaizen principles to manufacturing, which is a lean manufacturing Japanese philosophy of continuous improvement and elimination of waste. Kaizen, a Japanese term for "continuous improvement," is a management philosophy and practice focused on making incremental, small-scale enhancements to processes, products, and systems to achieve continuous and sustainable progress. Originating in Japan after World War II, it emphasizes the idea that even modest changes can lead to substantial improvements over time. Key principles of Kaizen include waste elimination, standardization, employee involvement, and the pursuit of continuous, manageable improvements. Kaizen events, or "blitzes," are often used to drive quick results by mobilizing cross-functional teams to address specific issues or process improvements. The Plan-Do-Check-Act (PDCA) cycle is a fundamental concept, guiding organizations to plan changes, implement them, check results, and act to make further refinements based on feedback. The benefits of Kaizen include improved efficiency, enhanced quality, cost reduction, and increased employee engagement. While it originated in manufacturing, Kaizen has been successfully applied in diverse sectors such as healthcare, software development, and services. Kaizen's long-term commitment to continuous improvement and its global influence make it a cornerstone of modern management practices, contributing to better processes, products, and outcomes in organizations worldwide. Spinoffs As A Key Value Creator Value creation though Spinoff is a strategic corporate action that involves separating a subsidiary or division from a parent company, resulting in two distinct, independently traded entities. Completely in line with the brothers’ vision of continuous improvement in their businesses, focusing on core competencies and improved operational efficiency. They have been active. Danaher Value Creation Through Spinoffs Edge Consulting Group The Latest Spinoff DHR is set to transform into a pure healthcare player consisting of its diagnostics, life science, and biotechnology businesses. The Spinoff of the Environmental & Applied Solutions (EAS) division (Veralto) will pave the way for DHR to become a fully integrated vertical healthcare chain provider. Although recent guidance from management indicates a subdued outlook for FY23 due to macroeconomic challenges, inventory adjustments, and cautious demand, it is anticipated that pent-up demand will alleviate these issues and gain momentum starting in Q1 FY24. Meanwhile, its modest leverage of ~1.1x and strong cash flow allow it to grow inorganically by strategically deploying its capital, thereby strengthening its product offering, as evident from its recent acquisition announcement of Abcam for $5.7bn. Danaher Value Creation
Abcam Acquisitions
11 Acquisitions
Abcam acquired 11 companies. Their latest acquisition was BioVision on August 02, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
8/2/2021 | Acquired | 5 | ||||
3/4/2020 | Grant | $0.1M | Acquired | 1 | ||
1/30/2020 | Acquired Unit | 1 | ||||
11/11/2019 | ||||||
11/11/2019 |
Date | 8/2/2021 | 3/4/2020 | 1/30/2020 | 11/11/2019 | 11/11/2019 |
---|---|---|---|---|---|
Investment Stage | Grant | ||||
Companies | |||||
Valuation | |||||
Total Funding | $0.1M | ||||
Note | Acquired | Acquired | Acquired Unit | ||
Sources | 5 | 1 | 1 |
Abcam Partners & Customers
10 Partners and customers
Abcam has 10 strategic partners and customers. Abcam recently partnered with NanoString Technologies on November 11, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/9/2022 | Licensee | United States | NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research SEATTLE & CAMBRIDGE , United Kingdom -- -- NanoString Technologies , Inc. , a leading provider of life science tools for discovery and translational research , and Abcam , a global life science company working together with researchers to advance science and enable faster breakthroughs , today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString Technologies , Inc. 's high-plex spatial multiomic solutions . | 4 | |
2/1/2022 | Partner | United States | Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform , and Abcam , a global innovator in life sciences reagents and tools , today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery , development and commercialization for diagnostic and research applications . | 3 | |
1/4/2022 | Partner | United States | Alamar Biosciences partners with Abcam to drive understanding of the human proteome FREMONT , Calif. and CAMBRIDGE , England , Jan. 4 , 2022 / PRNewswire / -- Alamar Biosciences , a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases , and Abcam , a global innovator in life sciences research tools , today announced a strategic partnership to further understanding of the human proteome . | 5 | |
11/2/2021 | Partner | ||||
10/28/2021 | Client |
Date | 11/9/2022 | 2/1/2022 | 1/4/2022 | 11/2/2021 | 10/28/2021 |
---|---|---|---|---|---|
Type | Licensee | Partner | Partner | Partner | Client |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research SEATTLE & CAMBRIDGE , United Kingdom -- -- NanoString Technologies , Inc. , a leading provider of life science tools for discovery and translational research , and Abcam , a global life science company working together with researchers to advance science and enable faster breakthroughs , today announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString Technologies , Inc. 's high-plex spatial multiomic solutions . | Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform , and Abcam , a global innovator in life sciences reagents and tools , today announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery , development and commercialization for diagnostic and research applications . | Alamar Biosciences partners with Abcam to drive understanding of the human proteome FREMONT , Calif. and CAMBRIDGE , England , Jan. 4 , 2022 / PRNewswire / -- Alamar Biosciences , a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases , and Abcam , a global innovator in life sciences research tools , today announced a strategic partnership to further understanding of the human proteome . | ||
Sources | 4 | 3 | 5 |
Abcam Service Providers
2 Service Providers
Abcam has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
IPO | Investment Bank | Bookrunner | |
Service Provider | ||
---|---|---|
Associated Rounds | IPO | |
Provider Type | Investment Bank | |
Service Type | Bookrunner |
Partnership data by VentureSource
Abcam Team
7 Team Members
Abcam has 7 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
David Cleevely | Founder | Current | |
Name | David Cleevely | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Compare Abcam to Competitors

Nuclera provides researchers with a desktop bioprinter capable of producing genes and proteins. Its bioprinter aims to allow researchers to accelerate discoveries and treatments by delivering on-demand desktop access. The company was founded in 2013 and is based in Cambridge, U.K.